Search Results - "OFNER, Clyde M"

Refine Results
  1. 1

    Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells by Nicoletto, Rachel E., Ofner, Clyde M.

    Published in Cancer chemotherapy and pharmacology (01-03-2022)
    “…Doxorubicin (DOX) is a chemotherapeutic agent frequently used for the treatment of a variety of tumor types, such as breast cancer. Despite the long history of…”
    Get full text
    Journal Article
  2. 2

    Carbodiimide Induced Cross-Linking, Ligand Addition, and Degradation in Gelatin by Cammarata, Christopher R, Hughes, Mitchell E, Ofner, Clyde M

    Published in Molecular pharmaceutics (02-03-2015)
    “…The water-soluble carbodiimide, 1-ethyl-3-(3-(dimethylaminopropyl)-carbodiimide (EDC) is widely used in protein chemistry. We used EDC-induced gelatin…”
    Get full text
    Journal Article
  3. 3

    Intracellular trafficking and cytotoxicity of a gelatine-doxorubicin conjugate in two breast cancer cell lines by Alvi, Mohammed M., Nicoletto, Rachel E., Eshmawi, Bayan A., Kim, Hyun (Kate), Cammarata, Christopher R., Ofner, Clyde M.

    Published in Journal of drug targeting (27-05-2020)
    “…Details of intracellular pathways of cytotoxicity remain unclear for doxorubicin conjugates being studied to treat breast cancer tumours. A high molecular…”
    Get full text
    Journal Article
  4. 4

    Adsorption and Degradation of Doxorubicin from Aqueous Solution in Polypropylene Containers by Wu, Darren C., Ofner, Clyde M.

    Published in AAPS PharmSciTech (01-03-2013)
    “…The purpose of this study was to examine doxorubicin adsorption in polypropylene containers as a function of pH and drug concentration based on anecdotal…”
    Get full text
    Journal Article
  5. 5

    Effect of Molecular Weight, Drug Load, and Charge of Gelatin-MTX Conjugates on Growth Inhibition of HL-60 Leukemia Cells by Chen, Chao-Sheng, Ofner, Clyde M. III

    Published in Pharmaceutical research (01-02-2009)
    “…Purpose Gelatin-methotrexate conjugates (G-MTX) with known molecular weight (MW), drug load, and charge were prepared and evaluated for growth inhibition on…”
    Get full text
    Journal Article
  6. 6

    Preparation, Drug Release, and Cell Growth Inhibition of a Gelatin: Doxorubicin Conjugate by Wu, Darren C., Cammarata, Christopher R., Park, Hyun Joo, Rhodes, Brian T., Ofner, Clyde M.

    Published in Pharmaceutical research (01-08-2013)
    “…Purpose To demonstrate the feasibility of a novel macromolecular delivery system for doxorubicin (DOX) which combines pH dependent DOX release with a high…”
    Get full text
    Journal Article
  7. 7

    Gelatin-methotrexate conjugate microspheres as a potential drug delivery system by Pica, Karen, Tchao, Ruy, Ofner, 3rd, Clyde M

    Published in Journal of pharmaceutical sciences (01-09-2006)
    “…Gelatin-methotrexate microspheres for intra-tumor administration have possibilities for minimizing systemic toxicities of methotrexate (MTX) and overcoming its…”
    Get more information
    Journal Article
  8. 8

    Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates by Ofner, Clyde M., Pica, Karen, Bowman, Bill J., Chen, Chao-Sheng

    Published in International journal of pharmaceutics (03-02-2006)
    “…Macromolecular gelatin-methotrexate conjugates have potential therapeutic advantages over the free drug. Conjugates with MTX:gelatin molar ratios (MR) ranging…”
    Get full text
    Journal Article
  9. 9

    Crosslinked gelatin matrices: release of a random coil macromolecular solute by Mwangi, Jane W., Ofner, Clyde M.

    Published in International journal of pharmaceutics (08-07-2004)
    “…The purpose of this investigation was to evaluate the effect of matrix crosslinking and solute size on release of a random coil macromolecular solute from…”
    Get full text
    Journal Article
  10. 10

    Multitemperature Stability and Degradation Characteristics of Pergolide Mesylate Oral Liquid by Shank, Brandon R., Ofner, Clyde M.

    Published in Journal of pharmacy practice (01-12-2010)
    “…The stability of pergolide mesylate in an oral aqueous liquid was studied. Stability and solubility data were used to determine the degradation characteristics…”
    Get full text
    Journal Article
  11. 11

    Crosslinking studies in gelatin capsules treated with formaldehyde and in capsules exposed to elevated temperature and humidity by Ofner, 3rd, C M, Zhang, Y E, Jobeck, V C, Bowman, B J

    Published in Journal of pharmaceutical sciences (01-01-2001)
    “…Incomplete in vitro capsule shell dissolution and subsequent drug release problems have recently received attention. A modified USP dissolution method was used…”
    Get more information
    Journal Article
  12. 12

    Abstract LB103: Investigating the roles of reactive oxygen species and lysosomes in the cytotoxicity of doxorubicin in breast cancer cells by Nicoletto, Rachel E., Ofner, Clyde M.

    Published in Cancer research (Chicago, Ill.) (01-07-2021)
    “…Abstract Background: Nuclear events play a well-established role in the cytotoxicity of doxorubicin (DOX). Other reported mechanisms include redox cycling for…”
    Get full text
    Journal Article
  13. 13

    Stability of Pergolide Mesylate Oral Liquid at Room Temperature by Shank, Brandon R, Ofner, Clyde M

    “…Pergolide mesylate (proprietary name Permax) is used to treat equine Cushing's syndrome. Since pergolide mesylate has been removed from the market, the tablets…”
    Get full text
    Journal Article
  14. 14

    Abstract 5387: Investigating the role of p53 in doxorubicin-mediated lysosome membrane permeabilization in breast cancer cells by Nicoletto, Rachel, Ofner, Clyde M.

    Published in Cancer research (Chicago, Ill.) (15-06-2022)
    “…Abstract Background: Doxorubicin (DOX) is a chemotherapeutic characterized by multiple mechanisms. Wild-type p53 (WTp53) may be activated in the presence of…”
    Get full text
    Journal Article
  15. 15

    Abstract 2954: Investigating the role of lysosome permeabilization for doxorubicin cytotoxicity in breast cancer cells by Nicoletto, Rachel E., Alvi, Mohammed M., Ofner, Clyde M.

    Published in Cancer research (Chicago, Ill.) (15-08-2020)
    “…Abstract Background: The nuclear cytotoxic pathway of doxorubicin (DOX) is well established. Other mechanisms include reactive oxygen specie (ROS) interactions…”
    Get full text
    Journal Article
  16. 16

    Abstract 2091: Lysosomal targeting of doxorubicin induces different membrane permeabilization and cytotoxicity in two breast cancer cell lines by Alvi, Mohammed, Nicoletto, Rachel, Eshmawi, Bayan A., Ofner, Clyde M.

    Published in Cancer research (Chicago, Ill.) (01-07-2019)
    “…Abstract Background: Lysosomal targeting has been investigated for the treatment of cancer but details of the resulting cytotoxicity remain unclear. The…”
    Get full text
    Journal Article
  17. 17

    Stability of pergolide mesylate oral liquid at room temerature by Shank, Brandon R, Ofner , III, Clyde M

    “…Pergolide mesylate (proprietary name Permax) is used to treat equine Cushing's syndrome. Since pergolide mesylate has been removed from the market, the tablets…”
    Get full text
    Journal Article
  18. 18

    Characterization and in vitro release of methotrexate from gelatin/methotrexate conjugates formed using different preparation variables by Kosasih, A, Bowman, Bill J, Wigent, Rodney J, Ofner, Clyde M

    Published in International journal of pharmaceutics (25-08-2000)
    “…The purpose of this study was to evaluate effects of preparation variables on the composition of gelatin-methotrexate conjugates, and to evaluate their in…”
    Get full text
    Journal Article
  19. 19

    Abstract 2527: Investigation of doxorubicin interference in flow cytometry measurements of apoptosis and necrosis by Nicoletto, Rachel E., Wilkes, Richard, Ofner, Clyde M.

    Published in Cancer research (Chicago, Ill.) (04-04-2023)
    “…Abstract Background: Doxorubicin (DOX) is frequently used for investigations of breast cancer using flow cytometry with fluorescent stains for apoptosis and…”
    Get full text
    Journal Article
  20. 20

    Characterization and in vitro methotrexate release from methotrexate/gelatin conjugates of opposite conjugate bond polarity by BOWMAN, Bill J, OFNER, Clyde M

    Published in Pharmaceutical research (01-10-2000)
    “…Our laboratory has previously prepared gelatin/ methotrexate (MTX) conjugates containing mixed conjugation sites and by-product crosslinking, both of which may…”
    Get full text
    Journal Article